As part of this, building robust direct-to-patient delivery models will be critical to ensuring timely, reliable access, supporting adherence, and reinforcing a differentiated patient experience
Discussing this with biotech/pharma sponsors and building some dose escalation buffer into a protocol to keep the participant in the study and manage these AEs (when possible) can be a good strategy to keep participants in the trial & improve their experience
This customizable medtech software platform is device-agnostic, regulatory-ready, and designed to accelerate connected health solutions
However, understanding its data matters because it represents where the field is heading
Nausea is one of the most commonly reported, especially during the initial stages of treatment
B1 (thiamine) deficiency, particularly common in alcohol users, damages peripheral nerves